10-K: United Therapeutics Reports Strong 2025 Revenue Growth

United Therapeutics Corporation reported an 11% increase in total revenues for 2025, driven by robust sales of Tyvaso DPI and Orenitram, alongside significant advancements in its organ manufacturing pipeline.

Summary

• Total revenues increased by 11% to $3,182.7 million in 2025, up from $2,877.4 million in 2024.
• Tyvaso DPI and Nebulized Tyvaso combined net product sales grew 16% to $1,878.2 million in 2025, representing 59% of total revenues.
• Tyvaso DPI net product sales alone increased by 25% to $1,292.5 million in 2025, primarily due to increased quantities sold and commercial utilization following Medicare Part D benefit redesign.
• Orenitram net product sales increased by 14% to $496.9 million in 2025, also benefiting from increased quantities sold and Medicare Part D benefit redesign.
• Remodulin net product sales decreased by 2% to $526.8 million in 2025.
• Unituxin net product sales decreased by 5% to $226.8 million in 2025.
• Adcirca net product sales increased by 26% to $30.0 million in 2025.
• Net income for 2025 was $1,334.7 million, up from $1,195.1 million in 2024.
• Diluted earnings per common share increased to $27.86 in 2025 from $24.64 in 2024.
• Research and development expenses increased by 14% to $550.0 million in 2025, primarily due to manufactured organ and drug delivery device projects.
• The TETON 2 Phase 3 study of Nebulized Tyvaso in IPF patients met its primary efficacy endpoint, showing a 95.6 mL improvement in absolute forced vital capacity (FVC) relative to placebo.
• The ADVANCE OUTCOMES Phase 3 study for ralinepag (oral PAH therapy) concluded enrollment in June 2025.
• The FDA cleared the Investigational New Drug (IND) application for the UKidney product's EXPAND study in January 2025, with the first transplant occurring in Q4 2025.
• The FDA cleared the IND for the UThymoKidney product's EXTEND clinical study in August 2025.
• Completed a $1.0 billion accelerated share repurchase program in 2025, repurchasing 2,642,498 shares.
• Accrued a liability of $74.1 million related to ongoing litigation with Sandoz through Q4 2025.
• The company maintains a strong cash and marketable investments position of $4,697.0 million as of December 31, 2025.
• The One Big Beautiful Bill Act of 2025 reinstated the option to deduct R&D expenditures in the period incurred, decreasing cash paid for income taxes and deferred tax assets for 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this 10-K as largely positive, reflecting strong financial performance driven by key products and significant progress in high-potential R&D areas like organ manufacturing. While competitive and legal challenges exist, the company's strategic advancements and financial health suggest a robust outlook.

Positives

• Total revenues increased by 11% in 2025, demonstrating strong overall business growth.
• Tyvaso DPI net product sales surged by 25% to $1,292.5 million, indicating strong market adoption and patient demand.
• Orenitram net product sales increased by 14% to $496.9 million, showing continued growth for the oral PAH therapy.
• The TETON 2 Phase 3 study for Nebulized Tyvaso in IPF met its primary endpoint, demonstrating significant improvement in FVC, which could lead to a new indication and substantial market opportunity.
• FDA clearance of INDs for UKidney (EXPAND study) and UThymoKidney (EXTEND study) marks significant progress in the organ manufacturing program, with the first UKidney transplant already performed.
• Successful test flight of a piloted hydrogen-electric powered helicopter in March 2025, advancing sustainable organ delivery.
• Net income increased by 11.7% to $1,334.7 million in 2025.
• Diluted EPS increased by 13.1% to $27.86 in 2025.
• The company completed a $1.0 billion accelerated share repurchase program in 2025, returning value to shareholders.
• The company's internal control over financial reporting was effective as of December 31, 2025, as attested by Ernst & Young LLP.

Negatives

• Nebulized Tyvaso net product sales remained flat, decreasing slightly by $1.1 million in 2025.
• Remodulin net product sales decreased by 2% to $526.8 million in 2025, likely due to generic competition.
• Unituxin net product sales decreased by 5% to $226.8 million in 2025, with limitations on supply to Japan causing delays in starting new patients.
• Increased competition from Merck's Winrevair and Liquidia's Yutrepia could negatively impact future revenues for treprostinil-based products.
• Ongoing litigation with Sandoz resulted in a $71.1 million judgment in 2024 and an additional $3.0 million accrual in 2025, with appeals pending.
• The Adcirca license agreement expires on December 31, 2026, which will lead to a loss of revenue from this product.
• The company recorded a $21.7 million impairment charge to write down certain property, plant, and equipment during Q2 2025.
• The One Big Beautiful Bill Act of 2025 significantly reduced funding for the Medicaid program, which could adversely affect sales of commercial products.
• The IRA's Medicare Part D manufacturer discounting program, effective January 1, 2025, will increase discounts on Orenitram and Tyvaso DPI, impacting revenues.

Risks

• Heavy reliance on sales of treprostinil-based therapies (Tyvaso DPI, Nebulized Tyvaso, Remodulin, Orenitram) means decreased sales of any could materially impact operations.
• Failure in clinical trials would prevent the sale of new products or expansion of existing product labels.
• Inability to compete successfully with established or newly developed drugs, including generic versions and new therapies like Merck's Winrevair and Liquidia's Yutrepia, could negatively impact operating results.
• Commercial success depends on adequate coverage and reimbursement from third-party payers, which are subject to increasing pricing and reimbursement pressures from government and private insurers.
• Manufacturing strategy exposes the company to significant risks, including supply chain disruptions, regulatory compliance, capacity limitations, and quality control issues, especially for complex manufactured organs.
• Reliance on third parties for critical activities (manufacturing, clinical trials, distribution) poses risks if these parties fail to perform satisfactorily.
• Reports of actual or perceived side effects and other adverse effects associated with products could decrease sales or lead to regulatory approval revocation.
• Negative attention from special interest groups, particularly regarding animal testing in organ manufacturing programs, could impair business operations.
• Inadequate insurance coverage may not protect against significant product liability claims.
• Failure to attract and retain key management and qualified scientific/technical personnel could impede business objectives.
• Non-compliance with extensive laws and regulations in the U.S. and other countries could delay or prevent commercialization of products.
• Government healthcare reform, including the IRA and potential future policies, could adversely affect revenue, costs, and results of operations.
• Potential enforcement action or penalties related to the 340B contract pharmacy policy.
• Increased scrutiny of patient assistance programs by governments and other third parties could reduce prices or demand for products.
• Improper handling of hazardous materials could expose the company to significant remediation liabilities.
• Increasing use of social media platforms and artificial intelligence-based software presents new risks and challenges, including data breaches and inaccurate information.
• Breach or termination of intellectual property license agreements could lead to loss of rights to develop, manufacture, and sell products.
• Intellectual property rights may not effectively deter competitors, leading to generic competition and patent challenges.
• Third parties may allege patent infringement, leading to costly litigation or loss of ability to sell related products.
• Cybersecurity incidents and other disruptions impacting networks, systems, or data may have a material adverse effect on the business.
• Inability to obtain additional financing, if needed, could limit product development and sales efforts.
• Portfolio of investments is subject to market, interest, operational, and credit risk that may reduce its value.
• Inability to successfully identify, finance, consummate, and/or integrate acquisitions could adversely affect business operations and financial position.
• The price of common stock can be highly volatile and may decline due to various market and company-specific factors.
• Provisions of Delaware law, charter, bylaws, and agreements could prevent or delay a change of control or management beneficial to public shareholders, especially as a Public Benefit Corporation.
• Shareholders must rely on stock appreciation for return on investment as the company has never paid cash dividends and does not intend to.

Future Outlook

The company anticipates near-term revenue growth will be primarily driven by continued growth in Tyvaso DPI sales, increased adoption of Tyvaso products for PH-ILD, continued growth in Orenitram prescriptions, and modest price increases. Mediumand longer-term growth is expected from new products, new indications for existing products (e.g., Nebulized Tyvaso for IPF/PPF), and new delivery devices. The ADVANCE OUTCOMES study for ralinepag is expected to release topline data in late Q1 or early Q2 2026. The company plans to continue building additional DPF facilities to meet future demand for xeno-organ products if approved, with capital expenditures budgeted at approximately $400 million through 2028.

Management Comments

• "Our mission is to transform the treatment of rare diseases and expand the availability of transplantable organs through innovative organ manufacturing technologies."
• "As a public benefit corporation (PBC), we aim to deliver meaningful impacts for our patients, our people, our shareholders, and other stakeholders."
• "We believe that Tyvaso DPI provides substantial lifestyle benefits to PAH and PH-ILD patients, as compared with Nebulized Tyvaso therapy."
• "We believe that Remodulin has many qualities that make it an appealing alternative to competitive continuously infused PAH therapies."
• "The majority of patients being treated with subcutaneous Remodulin in the United States are now using the Remunity or RemunityPRO Pump, and we believe that it is the only subcutaneous infusion system widely available in the United States for newly prescribed treprostinil patients."
• "Orenitram is the only FDA-approved, orally-administered prostacyclin analogue, and is the only oral PAH prostacyclin class therapy approved in the United States that is titratable to a maximum tolerated dose without a dose ceiling."
• "With advances in technology, we believe that creating an unlimited supply of tolerable manufactured organs and organ alternatives is now principally an engineering challenge, and we are dedicated to finding engineering solutions."
• "We anticipate that revenue growth over the near-term will be driven primarily by: (1) continued growth in sales of Tyvaso DPI; (2) continued growth in the number of PH-ILD patients prescribed Tyvaso DPI and Nebulized Tyvaso; (3) continued growth in the number of patients prescribed Orenitram; and (4) modest price increases for some of our products."
• "We believe that additional revenue growth in the mediumand longer-term will be driven by new products, new indications for existing products, and new devices to deliver our existing products."
• "We anticipate our existing DPF facility in Virginia and the two planned DPF facilities in Minnesota and Texas will provide an initial commercial supply of our xeno-organ products if and when they are approved by the FDA."
• "If our xeno-organ products are approved by the FDA, we likely will need to continue building additional DPF facilities to satisfy demand for these products."
• "While we have not seen a material impact on our net revenues as a result of Winrevair or Yutrepias launch to date, our net revenues could be materially impacted if either or both of these products gain significant market share or cause material price erosion for our existing products."

Industry Context

StockSavvy.ai notes that United Therapeutics operates in a highly competitive and evolving biopharmaceutical landscape, particularly in the rare disease and pulmonary hypertension markets. The strong performance of Tyvaso DPI highlights a successful product differentiation strategy against nebulized alternatives and new dry powder competitors like Liquidia's Yutrepia. The significant investment and progress in organ manufacturing (xenotransplantation, regenerative medicine) position the company as a leader in a nascent but potentially transformative field, addressing a critical unmet medical need for transplantable organs. The increasing R&D spend reflects the long-term nature of these ambitious projects. The impact of the IRA and generic competition underscores the ongoing pricing pressures and market dynamics faced by specialty pharmaceutical companies.

Comparison to Industry Standards

• The company's 2025 revenue per employee of approximately $2.25 million ranks near the top of its industry peer group, indicating high productivity.
• Voluntary employee turnover at 3.5% in 2025 is well below the industry average of 10% (based on Aon's Turnover Study for the Life Sciences/Biotech/Pharma Sector), suggesting strong employee retention and engagement.
• The company faces direct competition in PAH from large pharmaceutical companies like Johnson & Johnson (Uptravi), Gilead Sciences, Inc., Bayer Schering Pharma AG, GSK plc, and Merck (Winrevair), which often have greater financial and marketing resources.
• Merck's Winrevair, approved in March 2024, is a new activin signaling inhibitor for PAH, and while it hasn't materially impacted United Therapeutics' treprostinil sales yet, it represents a significant competitive threat, especially if prescribed earlier in the treatment paradigm.
• Liquidia's Yutrepia, a dry powder treprostinil formulation approved in May 2025, directly competes with Tyvaso DPI and Nebulized Tyvaso, intensifying competition in the inhaled prostacyclin market.
• Orenitram competes with Uptravi (selexipag), an oral IP-receptor agonist, with ralinepag aiming for a competitive advantage due to its once-daily dosing compared to Uptravi's twice-daily regimen. Johnson & Johnson reported global sales of Uptravi over $1.9 billion in 2025, including over $1.5 billion in U.S. sales, reflecting a 5% growth rate over 2024, setting a high benchmark for oral PAH therapies.
• In the IPF market, the company's Nebulized Tyvaso (TETON studies) aims to compete with established therapies like Boehringer Ingelheim's Ofev and Jascayd, and F. Hoffman-La Roche Ltd.'s Esbriet, as well as a generic version of Esbriet. Jascayd was approved in October 2025 for IPF and later for PPF, indicating a growing competitive landscape in fibrotic lung diseases.
• The xenotransplantation program, with FDA-cleared INDs for UKidney and UThymoKidney, represents pioneering efforts in organ manufacturing, with initial human transplants demonstrating progress in a field with limited direct commercial benchmarks.
• The company's investment in sustainable organ delivery via electric aircraft (BETA Technologies) and hydrogen-electric helicopters (Robinson Helicopter Company) positions it at the forefront of innovative logistics, potentially setting new industry standards for pharmaceutical and organ transport.

Corporate Governance

Legal Proceedings

• Sandoz Litigation: The company is engaged in litigation with Sandoz Inc. and Liquidia PAH, LLC (formerly RareGen) regarding alleged anticompetitive conduct related to Remodulin infusion devices. A final judgment was entered in favor of Sandoz for approximately $61.6 million in damages plus $9.0 million in prejudgment interest, with appeals pending before the U.S. Court of Appeals for the Third Circuit. The company has accrued $74.1 million for this liability.
• Liquidia Technologies, Inc. Litigation (Patent Infringement): The company has an ongoing patent infringement lawsuit against Liquidia concerning U.S. Patent No. 11,826,327, which covers improving exercise capacity in PH-ILD patients by inhaling treprostinil at specific dosages. Trial took place in June 2025, and the parties are awaiting the court's decision. If successful, the company believes Liquidia will be required to remove the PH-ILD indication from Yutrepia's label.
• Liquidia Technologies, Inc. Litigation (Trade Secret Misappropriation): The company filed a separate case against Liquidia and a former executive, Dr. Robert Roscigno, in North Carolina state court, alleging misappropriation of trade secrets related to Tyvaso. Motions for summary judgment by Dr. Roscigno and Liquidia were denied. A new, related complaint was filed on May 29, 2024, and is in its early stages.
• Liquidia Technologies, Inc. Litigation (Tyvaso DPI Patent Infringement): Liquidia filed a lawsuit against the company on April 21, 2025, alleging that Tyvaso DPI infringes U.S. Patent No. 10,898,494, which claims a method of treating pulmonary hypertension using inhaled treprostinil via a dry powder inhaler. The court granted the company's motion to stay this case.
• Liquidia Technologies, Inc. Litigation (Yutrepia Patent Infringement): The company filed a lawsuit against Liquidia on May 9, 2025, alleging Yutrepia infringes U.S. Patent No. 11,357,782, which claims a method of treating pulmonary hypertension using inhaled treprostinil with a specified dosage regimen. The company's motion for a preliminary injunction was denied.
• MSP Recovery Litigation: MSP Recovery Claims, Series LLC and other entities filed a class action complaint alleging RICO violations and state law claims related to the company's donations to a PAH fund. The U.S. District Court for the Southern District of Florida dismissed all claims against the company and Smiths Medical without prejudice in September 2022. A second amended complaint was filed, and the magistrate judge recommended dismissal of the plaintiffs' complaint against all defendants in its entirety with prejudice in March 2024. Plaintiffs filed an objection, and the district court judge's decision is pending.
• Humana and United Healthcare Litigation: Humana Inc. and United Healthcare Services, Inc. filed separate lawsuits in Maryland alleging RICO violations and state law claims similar to the MSP Recovery matter. The court dismissed both complaints in their entirety on March 25, 2024. Humana and United each filed new lawsuits in Maryland state court on April 24, 2024, with similar allegations. The court dismissed both lawsuits with prejudice on September 23, 2025, and Humana and United have appealed these decisions.

Related Party Transactions

• The company has an exclusive license agreement with Supernus Pharmaceuticals Inc. for Orenitram, requiring a single-digit percentage royalty based on net worldwide sales, which expires in Q4 2026.
• The company has an exclusive development and license agreement with DEKA Research & Development Corp. for the Remunity and RemunityPRO Pumps, funding development costs and paying product fees and a single-digit royalty on pump sales and Remodulin used with the system.
• The company has a worldwide, exclusive license and collaboration agreement with MannKind Corporation for Tyvaso DPI, paying a 10% royalty on net sales of Tyvaso DPI. MannKind also sold 1% of these royalties to Sagard Healthcare Funding Partners Borrowers 2 SPE, LP.
• The company has an exclusive license agreement with Arena Pharmaceuticals, Inc. (now owned by Pfizer Inc.) for ralinepag, with potential milestone payments and low double-digit, tiered royalties on net sales.
• The company acquired Miromatrix Medical Inc. in December 2023, with former shareholders receiving contingent value rights for a potential $1.75 per share payment upon the first implantation of mirokidney by the end of 2025.
• The company acquired IVIVA Medical, Inc. in October 2023, with potential earnout consideration structured as a 2% royalty on net sales of IVIVA's kidney products.
• The company pays The Scripps Research Institute a 1% royalty on Unituxin net product sales.
• The company will owe former securityholders of Revivicor a 5% royalty on net product sales of UHeart, UKidney, and UThymoKidney, plus certain milestone payments.

Stakeholder Impact

• Shareholders: Positive impact from increased revenues, net income, and EPS. Share repurchase programs demonstrate commitment to returning value. However, ongoing litigation and competitive pressures introduce risk to future stock price volatility.
• Patients: Continued development and commercialization of therapies for rare diseases (PAH, PH-ILD, IPF, PPF) and advancements in organ manufacturing technologies aim to provide a brighter future and address unmet medical needs. New products like Tyvaso DPI offer lifestyle benefits.
• Employees (Unitherians): The company's focus on challenging work, career advancement, autonomy, inspiring work environment, and competitive pay/benefits contributes to high engagement and low turnover. The PBC conversion reinforces commitment to employees as stakeholders.
• Customers (Specialty Pharmaceutical Distributors): Continued strong sales of key products benefit distributors. However, changes in distribution agreements or pricing pressures could impact their business.
• Suppliers/Partners: Ongoing collaborations with MannKind, DEKA, Lilly, and others are critical for product manufacturing and development. Any disruptions or changes in these relationships could impact supply and R&D timelines.
• Creditors: The company's strong financial position and zero outstanding balance on its $2.5 billion revolving credit facility indicate low credit risk.
• Regulatory Authorities: The company's extensive R&D and commercial activities are subject to rigorous FDA and international regulatory oversight. Compliance failures or delays in approvals could have significant adverse impacts.

Next Steps

• Data readout from the TETON 1 study of Nebulized Tyvaso in IPF patients is expected late in Q1 or early in Q2 2026.
• Topline data from the ADVANCE OUTCOMES study of ralinepag is planned for release late in Q1 or early in Q2 2026.
• Miromatrix is planning to commence a Phase 2 study for miroliver ELAP.
• The company intends to use data from TETON 1 and TETON 2 studies to support a supplemental NDA to the FDA to add IPF to the labeled indications for Nebulized Tyvaso.
• The company will consider seeking amendments to marketing authorizations for Nebulized Tyvaso in other countries to include IPF and/or PPF indications, and approval in new countries.
• A Phase 2 study of treprostinil SMI to treat patients with PH-COPD is planned.
• If ralinepag's ADVANCE OUTCOMES study is successful, the company plans to develop an oral triple-combination therapy.
• The EXPAND study of the UKidney product is ongoing and expected to enroll an initial cohort of six ESRD patients, expanding to up to 50 participants, with results intended to support a BLA.
• The EXTEND clinical study of the UThymoKidney product is expected to commence, similar in size and scope to the EXPAND study.
• The company plans to seek NADA approval for the pig lineage containing ten genetic modifications for UKidney and UHeart products.
• Construction of two additional DPF facilities in Minnesota and Texas is ongoing, with plans for potentially larger cGMP DPF facilities for commercial use.
• The company is in the process of qualifying its RTP facility to produce the primary commercial supply of ralinepag if approved.
• The company has initiated efforts to qualify a contract manufacturer as a second manufacturing source for dinutuximab (Unituxin active ingredient).
• The company is engaged in further efforts to develop alternative pumps to administer Remodulin.
• The company has budgeted approximately $400 million for capital expenditures during 2026 and through the end of 2028 for facility construction.
• Miromatrix is developing miroliver and mirokidney, fully implantable manufactured organ alternatives.
• The CLES premarket approval application is under review by the FDA.
• The company will continue to vigorously enforce its intellectual property rights related to Tyvaso DPI and Nebulized Tyvaso, and defend against Liquidia's patent infringement lawsuit.
• Appeals are pending in the Sandoz litigation and the Humana/United Healthcare lawsuits.
• Several executives and directors have adopted Rule 10b5-1(c) trading plans for stock option exercises and sales commencing no earlier than March 2, 2026, and ending no later than December 31, 2026.

Key Dates

Recommendation

United Therapeutics demonstrates strong financial performance with significant revenue and earnings growth, primarily driven by its flagship Tyvaso DPI product. The successful clinical trial results for Nebulized Tyvaso in IPF and the substantial progress in the organ manufacturing pipeline (UKidney, UThymoKidney) indicate robust future growth potential and a strong commitment to addressing unmet medical needs. While the company faces competitive pressures and ongoing litigation, its solid cash position, strategic investments in R&D, and share repurchase programs underscore a healthy financial outlook and a proactive approach to value creation. The long-term vision in organ manufacturing, though capital-intensive, presents a transformative opportunity that could significantly enhance future value. Seasoned investors would likely view the current performance and pipeline as compelling for a 'buy' recommendation, focusing on the company's innovation and market leadership in specialized therapeutic areas.

Keywords

Pulmonary Arterial Hypertension, PAH, Pulmonary Hypertension Associated with Interstitial Lung Disease, PH-ILD, Idiopathic Pulmonary Fibrosis, IPF, Progressive Pulmonary Fibrosis, PPF, Treprostinil, Tyvaso DPI, Nebulized Tyvaso, Remodulin, Orenitram, Unituxin, Adcirca, Ralinepag, Xenotransplantation, Organ Manufacturing, Regenerative Medicine, Ex Vivo Lung Perfusion, EVLP, Biotechnology, Pharmaceuticals, SEC Filing, 10-K, Public Benefit Corporation, Rare Diseases, Oncology, Neuroblastoma